American Association for Cancer Research

April is National Cancer Control Month, and there is no better time to step up and advocate for lifesaving medical research. A recent report from ’€œ PBS NewsHour ’€ highlights the crippling effects of sequestration on funding for cancer research. The story of the Riggins laboratory is just one example of labs all over the country having to slow or stop promising research due to a lack of funding. According to the American Cancer Society’€™s 2013 report , more than half a million Americans are expected to die from cancer this year alone. Cancer ranks as the second most common disease, exceeded only by heart disease. Some aspects of cancer risk are inherent, such as having a faulty gene...
Dear Research Advocate, On Tuesday, the president announced a new $100 million brain research initiative (BRAIN) that will involve NSF, NIH and DARPA and include support from a number of independent research institutes and private foundations. The fact that the White House has announced this ’€œmoonshot’€ is an important sign that research is securing its rightful role as a top national priority, which is critical to our collective goal of eliminating sequestration and aligning research funding with scientific opportunity. The president will include BRAIN in his FY14 budget, which will be released April 10. In CQ , House Majority Leader Eric Cantor (R-VA) expressed support for the BRAIN...
Dear Research Advocate, Congress has passed a spending bill for what remains of the current fiscal year, which ends September 30. Preliminary agency funding levels have been reported by Nature . The appropriations process remains important for making up some small amount of the ground lost to sequestration, but as long as sequestration remains the law of the land, annual cuts to NIH, FDA and our nation’€™s other health research agencies are all but assured ; and with it, the insidious ripple effect of damage to grantees, vendors, and the pharma, bio and device industries that partner with researchers to develop the products patients await. That’€™s the bottom line. We must remind our...

Pages